Edwards Lifesciences Corporation (NYSE:EW) Receives $97.09 Consensus PT from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned an average rating of “Moderate Buy” from the twenty-five analysts that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $98.7273.

EW has been the topic of several analyst reports. Evercore reaffirmed an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. TD Cowen restated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. BTIG Research boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Mizuho raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Robert W. Baird increased their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,577 shares of company stock valued at $3,855,527 over the last three months. 0.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $28,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 3.2%

Shares of NYSE EW opened at $87.22 on Monday. The firm has a 50-day moving average price of $87.12 and a 200 day moving average price of $83.92. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $50.22 billion, a price-to-earnings ratio of 46.39, a price-to-earnings-growth ratio of 2.26 and a beta of 0.86. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.